🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

1) We recently reported our experience with post-treatment SPECT in PSMA RLT and its impact on management. Nearly 50% of patients had a change in treatment! Post-treatment imaging has a huge impact, and allows us to follow disease at each treatment (bit.ly/4cqch8Y)

2) Post-treatment imaging is a unique aspect of lutetium-based theranostics, which is markedly cheaper than PET based imaging response. In 28%, progression was noted and treatment stopped, and in 20%, treatment was delayed due to good response (below).

Theranostics AANMS Theranostics Course is underway in Brisbane. Not just featuring nuclear medicine, but also medical oncology, radiology, surgery, endocrinology and more. And thanks Jennifer Martin - Physician and Board Director for attending: highlighting the importance of nuclear medicine speciality The Royal Australasian College of Physicians

Prof Oliver Sartor presenting at Theranostics AANMS ... Nice slide on What we do not know from VISION.

At ⁦⁦Theranostics AANMS⁩ conference and realised how much theranostic drug development and therapy are already revolutionizing care for many diseases in adults and children ⁦Sze Ting Lee⁩ ⁦Michael Hofman⁩ ⁦Louise Emmett⁩ ⁦The Royal Australasian College of Physicians⁩

Jennifer Martin - Physician and Board Director Theranostics AANMS Sze Ting Lee Louise Emmett The Royal Australasian College of Physicians Thanks so much for attending! Highlighting the importance of nuclear medicine specialist in The Royal Australasian College of Physicians

Dear Colleagues, A wam welcome to Lugano Switzerland for: 🔬 #APCCC25 Diagnostics: 27-28 February 2025 REGISTER AT: apccc.org 🗓️Mark your Calendar!! We look forward to continuing these crucial #ProstateCancer conversations in Lugano🇨🇭 Sincerely Ken Herrmann

I find it odd to hear oncologists call themselves or colleagues Giants Rising stars Rock stars Most of the decline in cancer deaths is just due to smoking cessation. Many 'Giants' developed a drug with a 1 month PFS gain.

Pleased to share our recent European Urology manuscript on post treatment PSA declines and patient survival and long term outcomes after 177Lu-PSMA-617 therapy from the VISION trial! DCI Center for Prostate & Urologic Cancers @morr316 Novartis Cancer Duke Cancer sciencedirect.com/science/articl…

Movember Australia have contributed to Australia being world leaders in development of PSMA PET/CT and PSMA theranostics... They have put together this great video featuring Louise Emmett Michael Tull youtu.be/65U7MoyAF2c?fe…

silke gillessen presenting results from PEACE-3 trial of Enzalutamide vs Enzalutamide + Radium-223 in mCR #ProstateCancer Practice-changing data with rPFS 0.69 & OS 0.69 favouring Enza + Ra-223! UroToday.com OncoAlert Gil Morgan, MD ESMO - Eur. Oncology #ESMO24

PEACE-3 reinvigorating the role of Radium-223? Improves rPFS and likely OS as first line treatment in mCRPC in combination with enza. Results much more impressive than I expected! silke gillessen #ESMO24 But has landscape already changed with LuPSMA?? Should we consider Ra-223

Challenge Your Expert Session #ProstateCancer kicking off in Valencia Hall 5. Come along and challenge Prof Ken Herrmann on "radioligand Theranostics in prostate cancer: status quo and new developments" #ESMO24 ESMO - Eur. Oncology

☢ UpFrontPSMA "Live #ESMO24": Lutetium-177 PSMA-617 followed by docetaxel improved anti-tumour activity in men with new diagnosis of metastatic hormone-sensitive prostate cancer compared with docetaxel alone, without increased side effects 🔥Hot off the press The Lancet Oncology:

Great slide from Christopher Sweeney, MBBS #ESMO24 highlighting a model of personalising prostate cancer care in 2024!

Why do the TheraP and VISION trials show different effects of Lu-177 PSMA on survival in advanced prostate cancer? It may be due to different comparison treatments. jamanetwork.com/journals/jaman… Martin Stockler Ian Marschner Michael Hofman Ian Davis (Bluesky @profiand) Louise Emmett

Recent grants awarded to Jeremie Calais will help support two clinical trials that will explore new strategies for utilizing the radiation-emitting targeted therapy 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer. bit.ly/3XWty62

A great talk by Nick James also on @Prof-Nick-James.bsky.social at #PCFRetreat24 on the STAMPEDE trial legacy! PCF Science

SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617 jnm.snmjournals.org/content/early/…

Moving toward precision response assessment and dynamic risk startification by SPECT/CT in mCRPC receiving LuPSMA! #PSMA #Theranostics Fred Hutch Cancer Center University of Washington Louise Emmett Michael Hofman Thomas Hope jnm.snmjournals.org/content/early/…